A Phase II Study Evaluating JAB-21822 Monotherapy in Adult Patients With Pancreatic Cancer and Other Solid Tumors Harboring the KRAS p.G12C Mutation.

Inclusion Criteria:

• Patients with the KRAS p.G12C mutation confirmed through testing using prospectivelyvalidated companion diagnostic reagents or clinical trial assay (CTA) methods.

• Histologically or cytologically confirmed locally advanced unresectable ormetastatic solid tumors (excluding NSCLC and CRC).

• Patients with pancreatic cancer must have progressed or been intolerant to priorgemcitabine-based chemotherapy regimens or FOLFIRINOX/mFOLFIRINOX/NALIRIFOXtreatment. Patients with other types of solid tumors must have progressed or beenintolerant to prior systemic therapies and lack satisfactory alternative treatmentoptions.

Exclusion Criteria:

• Previously received a KRAS G12C inhibitor.

• History of interstitial lung disease, non-infectious pneumonia, or uncontrolled lungdisease (including pulmonary fibrosis, acute lung disease, etc.) with clinicalsymptoms.

• Uncontrolled pleural effusion, pericardial effusion, or ascites.

• Mean QT interval corrected for heart rate using Fridericia's formula (QTcF) ≥470 mscalculated from 3 electrocardiograms.

• Use of a drug with known risk of torsades de points (TdP) within 14 days prior tothe first dose.